ArticleEndocrine2021
Chronic hypoparathyroidism and treatment with teriparatide.
Article in Endocrine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 20 citations in OpenAlex.
- Efficacy and safety of parathyroid hormone analogs therapy on hypoparathyroidism: a meta-analysis.Frontiers in endocrinology · 2026Pooled it
- Safety and Efficacy of PTH 1-34 and 1-84 Therapy in Chronic Hypoparathyroidism: A Meta-Analysis of Prospective Trials.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2022Pooled it
- [Resolution of the Joint Meeting of the Expert Council "Hypoparathyroidism in the Era of Complex Problems and Breakthrough Technologies"].Problemy endokrinologii · 2026Article
- Management of patients with hypoparathyroidism: a Delphi consensus analysis.Journal of endocrinological investigation · 2026Article
- Clinical Characteristics, Treatment Patterns, and Complications in Permanent Hypoparathyroidism: A Large Retrospective Cross-Sectional Study.Calcified tissue international · 2026Article
- First Reported Use of Recombinant Parathyroid Hormone in Kenny-Caffey Syndrome Type 2: A Case Report and Literature Review.Diseases (Basel, Switzerland) · 2026Review
- Hypoparathyroidism: a brief historical overview for clinicians.Frontiers in endocrinology · 2026Review
- Biochemical and clinical outcomes of once-daily teriparatide in refractory chronic hypoparathyroidism: A single-center experience.Northern clinics of Istanbul · 2026Article
- The Chronobiology of Hormone Administration: "Doctor, What Time Should I Take My Medication?"Endocrine reviews · 2025Review
- Continuous Subcutaneous Delivery of rhPTH(1-84) and rhPTH(1-34) by Pump in Adults With Hypoparathyroidism.Journal of the Endocrine Society · 2024Article
- Forestalling Hungry Bone Syndrome after Parathyroidectomy in Patients with Primary and Renal Hyperparathyroidism.Diagnostics (Basel, Switzerland) · 2023Review
- Treatment options in hypoparathyroidism.Archives of endocrinology and metabolism · 2022Review
- Multicenter retro-prospective observational study on chronic hypoparathyroidism and rhPTH (1-84) treatment.Journal of endocrinological investigation · 2022Observational
- Which physical activity in patients affected by hypoparathyroidism? A review of the literature and practical recommendations.Journal of endocrinological investigation · 2022Review
- Hypoparathyroidism: State of the Art on Cell and Tissue Therapies.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
purposeChronic hypoparathyroidism is usually treated with calcium and active vitamin D metabolites or analogs, despite the fact that their chronic use can lead to long-term complications. The use of hormone replacement therapy with PTH peptides [teriparatide and rhPTH (1-84)] has therefore been proposed. The main purpose of this study was to investigate the efficacy of teriparatide dose at 20 µg once or twice daily, in order to maintain normocalcemia reducing standard treatment, in adult patients with chronic hypoparathyroidism not well controlled with conventional treatment.
methodsThe study was a Phase III, open-label, non-comparative, clinical investigation (study period: 3 months), at a tertiary care clinical research center. Thirty patients with chronic hypoparathyroidism were screened, and 12 started teriparatide. After the optimization phase (0-4 weeks), calcium and calcitriol supplements were progressively reduced, while teriparatide 20 µg once daily was administered (5-7 weeks), and then could be titrated up to 20 µg twice daily (7-17 weeks). The main outcome measures included serum and urinary biochemical exams and Rand 36-Item Short Form Health Survey.
resultsThis study showed that teriparatide 20 µg once daily was insufficient to discontinue calcium and calcitriol supplements to maintain normal serum calcium concentrations. Conversely, for more than half of patients treated with teriparatide 20 µg twice daily, calcium and calcitriol administration was avoidable, but in some cases at the expense of serum calcium and phosphate oscillations.
conclusionsSince intervention trials evaluating the efficacy and safety of teriparatide in hypoparathyroid patients are not yet available, the routine use of this molecule poses some doubts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.